Author:
Hamada Taiji,Akahane Toshiaki,Yokoyama Seiya,Higa Nayuta,Kirishima Mari,Matsuo Kei,Shimokawa Michiko,Yoshimoto Koji,Tanimoto Akihide
Abstract
AbstractUnderstanding human genome alterations is necessary to optimize genome-based cancer therapeutics. However, some newly discovered mutations remain as variants of unknown significance (VUS). Here, the mutation c.1403A > G in exon 10 of the platelet-derived growth factor receptor-alpha (PDGFRA) gene, a VUS found in adult glioblastoma multiforme (GBM), was introduced in human embryonal kidney 293 T (HEK293T) cells using genome editing to investigate its potential oncogenic functions. Genome editing was performed using CRISPR/Cas9; the proliferation, drug sensitivity, and carcinogenic potential of genome-edited cells were investigated. We also investigated the mechanism underlying the observed phenotypes. Three GBM patients carrying the c.1403A > G mutation were studied to validate the in vitro results. The c.1403A > G mutation led to a splice variant (p.K455_N468delinsN) because of the generation of a 3’-acceptor splice site in exon 10. PDGFRA-mutated HEK293T cells exhibited a higher proliferative activity via PDGFRα and the cyclin-dependent kinase (CDK)4/CDK6-cyclin D1 signaling pathway in a ligand-independent manner. They showed higher sensitivity to multi-kinase, receptor tyrosine kinase, and CDK4/CDK6 inhibitors. Of the three GBM patients studied, two harbored the p.K455_N468delinsN splice variant. The splicing mutation c.1403A > G in PDGFRA is oncogenic in nature. Kinase inhibitors targeting PDGFRα and CDK4/CDK6 signaling should be evaluated for treating GBM patients harboring this mutation.
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Landrum, M. J. et al. ClinVar: Public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, D862–D868 (2016).
2. Chakravarty, D. et al. OncoKB: A precision oncology knowledge base. JCO Precis. Oncol. 1, 1–16 (2017).
3. Rivera-Muñoz, E. A. et al. ClinGen variant curation expert panel experiences and standardized processes for disease and gene-level specification of the ACMG/AMP guidelines for sequence variant interpretation. Hum. Mutat. 39, 1614–1622 (2018).
4. Tate, J. G. et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941–D947 (2019).
5. Louis, D. N., von Deimling. A., & Cavenee, W. K. Diffuse astrocytic and oligodendroglial tumours–Introduction. in WHO Classification of Tumours of the Central Nervous System (eds. Louis, D.N. et al.). 12–13. (IARC, 2016).
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献